1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sun Pharma Advanced Research Co. Ltd.

Sun Pharma Advanced Research Co. Ltd.

173.15
INR
-6.35
(-3.54%)
48.84EPS
4.80P/E
76.08BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
7.01
6.58
6.81
7.35
3.15
7.15
2.93
9.65
5.22
8.39
2.33
2.21
1.21
58.86
Basic EPS, GAAP
1.27
-1.67
-2.96
-4.84
-7.94
-5.69
-11.92
-5.77
-7.73
-7.82
-11.93
-10.55
47.86
48.84
Free Cash Flow per Basic Share
1.39
-2.08
-2.39
-5.55
-8.68
-7.23
-10.11
-6.03
-9.16
-2.97
-14.04
-11.42
-8.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.84
4.19
1.27
6.41
7.36
11.3
-0.71
-6.42
1.15
15.8
3.88
-6.69
41.26
- -
Tangible Book Value per Share
5.84
4.19
1.27
6.41
7.35
11.28
-1.83
-6.45
0.3
15.02
2.56
-8.34
39.06
- -
Basic Weighted Avg Shares
238
237
237
246
248
256
262
262
263
285
325
325
325
324
Sales/Revenue/Turnover
1,670
1,557
1,613
1,810
783
1,829
768
2,530
1,372
2,388
755
718
391
19,095
Operating Margin (%)
18.09
-26.92
-43.49
-72.24
-320.44
-83.18
-410.02
-57.68
-142.86
-93.66
-544.71
-465.49
4,084.29
84.17
Depreciation Expense
36
72
76
82
82
76
95
109
102
118
125
124
102
97
Net Income, GAAP
303
-395
-700
-1,190
-1,970
-1,454
-3,124
-1,511
-2,034
-2,226
-3,872
-3,425
15,532
15,843
Effective Tax Rate (%)
11.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
18.15
-25.38
-43.4
-65.76
-251.73
-79.53
-406.7
-59.75
-148.19
-93.22
-512.56
-477.26
3,967.49
82.97
Working Capital
713
258
-588
503
591
1,623
-1,682
-1,702
-1,003
2,760
43
-3,480
11,083
- -
LT Debt
38
33
27
22
16
11
64
1,167
24
126
107
1,069
17
- -
Total Equity
1,393
998
300
1,582
1,847
2,962
-186
-1,683
312
5,128
1,258
-2,169
13,388
- -
Return on Invested Capital (%)
15.99
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
21.13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
24.48
-33.06
-107.81
-126.5
-114.91
-60.48
- -
- -
- -
-81.83
-121.28
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5,561
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
17
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
325
325
325
Market Capitalization
43,632
37,190
76,084

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
18,624
- -
Cash, Cash Equivalents & STI
- -
13
- -
Accounts Receivable, Net
- -
83
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
7,541
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5,561
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
155.85%
71.7%
-717.12%
Free Cash Flow
56.71%
75.82%
-29.15%
Net Income, GAAP
-27.45%
-89.41%
-553.48%
Sales/Revenue/Turnover
16.99%
-18.11%
-45.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
168
129
149
272
718
2026
96
79
85
18,532
391
2027
399
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.96
-3.31
-2.45
-1.84
-10.55
2026
-1.6
-2.34
-2.48
54.27
47.86
2027
-0.64
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anilkumar Raghavan
Full Time Employees
466
Sector
Health technology
Industry
Pharmaceuticals: major
Address
17-B, Mahal Industrial Estate Mumbai MA India 400093
IPO Date
Jul 18, 2007
Website
sparc.life
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sun Pharma Advanced Research Company Limited (SPARC.NS) is a clinical-stage biopharmaceutical company focused on the research, development, and innovation of novel therapeutics and drug delivery systems to enhance patient care globally; core products and pipeline candidates target oncology through initiatives like the antibody-drug conjugate SBO-154 for solid tumors and BCR-ABL1 tyrosine kinase inhibitors; neurology, including assets for Parkinson's disease in Phase II trials and neurodegeneration programs pursuing novel pathways; immunology; ophthalmology to improve patient compliance; and dermatology with differentiated therapies for medical dermatology; the company also advances novel chemical entities (NCEs) and novel drug delivery systems (NDDS). SPARC operates primarily from its headquarters in Mumbai, India, with additional facilities in Pune, Maharashtra; founded in 2006 through a demerger from Sun Pharmaceutical Industries Limited, it maintains a single reportable segment in pharmaceutical research and development across India and international markets, employing approximately 316 people. Recent developments include the submission of an Investigational New Drug (IND) application to the US FDA in March 2025 for SBO-154 ahead of its Phase I clinical trial in solid tumors; incorporation of a new wholly owned subsidiary, Genokine Biotech Limited, in July 2025 to support strategic expansion, though it remains pre-commercial; and increased capital expenditures to ₹2,314 lakhs alongside intangible assets under development reaching ₹7,121 lakhs as of September 2025, reflecting heightened R&D investments amid ongoing clinical progress despite reported operational losses.